Follow Humana to never miss an important update.
Humana is launching a new model for cancer care that removes the need for prior authorization, the process where doctors must get an insurer's approval before starting a treatment. By working with Evolent and the American Oncology Network, the company is allowing doctors to follow pre-approved clinical paths instead of waiting for individual case reviews.
This is a smart move to lower the administrative costs that often frustrate both doctors and patients. For a long-term owner, it shows Humana is finding ways to make its insurance plans more attractive and efficient without sacrificing care quality. Reducing these hurdles can lead to better health outcomes and lower long-term costs by getting patients into the right treatments faster.
Source: Business Wire
Humana has started a process to buy back several of its outstanding notes, which are essentially IOUs the company issued to borrow money. By offering to pay cash for these debts now, the company can reduce its future interest payments and manage its balance sheet more effectively. This is a routine financial move for a company of this size. It suggests Humana has enough cash on hand to comfortably settle these obligations early, but it does not change the core outlook for its insurance or clinical businesses.
Source: Business Wire
After Humana reported its November results, we updated our fair value and raised our quality score to 3.7. We now rate management and the handling of the company’s biggest risks more highly. We raised our profit expectations for the year to $9.50 per share and added the new joint venture with BlackRock to what we track. We also adjusted our medical cost projections to account for the insurance division spending 93.7% of its premium revenue on care.
Humana reported a loss of $0.70 per share for the third quarter, which was better than the $1.00 loss analysts expected. While the company is losing money this quarter, it is a planned dip as it spends heavily to sign up new members. Revenue reached $41.16 billion, slightly ahead of expectations.
The most important detail for investors is the benefit ratio, which measures how much of every premium dollar the company pays out for medical care. That ratio was 93.7 percent, better than management's own forecast. This suggests that the spike in medical costs that has hit the insurance industry lately is starting to stabilize. Because of this, Humana raised its full-year profit goal to at least $9.50 per share, up from its previous target of $9.00. Its CenterWell business, which runs primary care clinics and pharmacies, also grew its patient count by 30 percent this year. This is a key part of the company's long-term plan to control costs by treating patients in its own facilities rather than just paying outside hospital bills.
See the full quarter, and how our tracked metrics did
Source: 8-K filing
Humana is expanding its digital link with athenahealth to handle prior authorizations, which are the approvals doctors must get from insurers before certain treatments. By moving this process into the software physicians already use, the company aims to cut down on paperwork and help patients get care faster. This is a small but useful step in Humana's broader plan to lower its own administrative costs. Making it easier for doctors to work with the insurer can also help keep them in Humana's network, which is important for keeping its 6 million members satisfied.
Source: Business Wire
Management has cleared its own profit targets for eight straight quarters. This perfect record of small, steady beats shows a team that sets conservative bars and knows how to hit them.
| Expectation | |
|---|---|
| EPS | $-7.60 |
| Revenue | $41.35B |